Kratom faces scrutiny over health risks
Be the first to know
Get browser notifications for breaking news, live events, and exclusive reporting.
Kratom is commonly marketed as a health wonder, but the FDA warns of “serious adverse effects.” It has even been blamed for several deaths. Mark Strassmann reports.
Be the first to know
Get browser notifications for breaking news, live events, and exclusive reporting.
The latest variant of the COVID-19 virus, JN.1, is now responsible for an estimated 15% to 29% of cases in the U.S. as of Dec. 8, according to a posted update from the Centers for Disease Control and Prevention (CDC). JN.1, which is currently the country’s fastest growing variant, is expected to continue to increase…
The last bedtime of 17-month-old Hayden Fell’s life was heartbreakingly normal. Crib video shows the toddler in pajamas playing happily as his parents and sister sang “Wheels on the Bus” with his twin brother. The next morning, Hayden’s dad couldn’t wake him. The tot had become one of several hundred seemingly healthy U.S. toddlers and…
Dr Will Welfare, UKHSA Incident Director, said: “This is the first time we have detected this virus in humans in the UK. As soon as we get such a result, we immediately start work with partners to learn everything we can about it. Our investigation is continuing at pace and we will publish further information…
Making breast cancer screenings an annual event could save women’s lives, new research suggests. In a study led by Epic Research, a health analytics firm based in Verona, Wisconsin, women who were screened for breast cancer on a yearly basis were shown to have a 17% lower risk of death by any cause compared to…
Health 25 August 2023, 6:39 pm 1 minute Reuters exclusively reported that Novo Nordisk has hired Thermo Fisher as its second contract manufacturer for its hugely popular weight-loss drug Wegovy. Novo Chief Financial Officer Karsten Munk Knudsen told Reuters in May the company had signed up a second contract manufacturer in the United States, but…
Bristol Myers Squibb on Friday announced it agreed to buy biopharmaceutical company Karuna Therapeutics for $14 billion in cash, or $330 per share. Karuna’s stock closed up more than 47% on the news Friday, hitting $317.85 a share. Bristol Myers Squibb shares closed up 2%. The deal will help expand Bristol Myers’ drug pipeline after…